Literature DB >> 9656134

Risperidone for aggression and self-injurious behavior in adults with mental retardation.

S A Cohen1, K Ihrig, R S Lott, J M Kerrick.   

Abstract

Risperidone has proven efficacy with reduced likelihood of causing extrapyramidal symptoms in the treatment of schizophrenia. Initial work suggests its utility in the management of aggression and self injury in patients with mental retardation. The use of risperidone in eight adult patients with moderate to profound mental retardation is described. Risperidone in these individuals was associated with significant reduction in aggression and self injurious behavior. Side effects were primarily those of sedation and restlessness. These cases illustrate the possible utility of risperidone in the treatment of aggression and self injury in adult patients with moderate to profound mental retardation.

Entities:  

Mesh:

Substances:

Year:  1998        PMID: 9656134     DOI: 10.1023/a:1026069421988

Source DB:  PubMed          Journal:  J Autism Dev Disord        ISSN: 0162-3257


  13 in total

1.  Increased blood serotonin and platelets in early infantile autism.

Authors:  E R Ritvo; A Yuwiler; E Geller; E M Ornitz; K Saeger; S Plotkin
Journal:  Arch Gen Psychiatry       Date:  1970-12

2.  Pipamperone (Dipiperon, R3345) in troublesome mental retardates: a double-blind placebo controlled cross-over study with long-term follow-up.

Authors:  J C van Hemert
Journal:  Acta Psychiatr Scand       Date:  1975-10       Impact factor: 6.392

3.  Tardive dyskinesia in the mentally retarded: comparison of prevalence, risk factors and topography with a schizophrenic population.

Authors:  S Cohen; A Khan; Y Zheng; J Chiles
Journal:  Acta Psychiatr Scand       Date:  1991-03       Impact factor: 6.392

4.  Risperidone and tardive dyskinesia: a case report.

Authors:  D E Addington; J A Toews; J M Addington
Journal:  J Clin Psychiatry       Date:  1995-10       Impact factor: 4.384

5.  Neuroleptic-induced tardive dyskinesia.

Authors:  D G Daniel; K Smith; T Hyde; M Egan
Journal:  Am J Psychiatry       Date:  1996-05       Impact factor: 18.112

6.  Risperidone-induced tardive dyskinesia.

Authors:  R D Buzan
Journal:  Am J Psychiatry       Date:  1996-05       Impact factor: 18.112

7.  The use of clozapine in a mentally retarded and aggressive population.

Authors:  S A Cohen; M T Underwood
Journal:  J Clin Psychiatry       Date:  1994-10       Impact factor: 4.384

8.  Risperidone as add-on therapy in behavioural disturbances in mental retardation: a double-blind placebo-controlled cross-over study.

Authors:  R Vanden Borre; R Vermote; M Buttiëns; P Thiry; G Dierick; J Geutjens; G Sieben; S Heylen
Journal:  Acta Psychiatr Scand       Date:  1993-03       Impact factor: 6.392

9.  A Canadian multicenter placebo-controlled study of fixed doses of risperidone and haloperidol in the treatment of chronic schizophrenic patients.

Authors:  G Chouinard; B Jones; G Remington; D Bloom; D Addington; G W MacEwan; A Labelle; L Beauclair; W Arnott
Journal:  J Clin Psychopharmacol       Date:  1993-02       Impact factor: 3.153

Review 10.  Risperidone.

Authors:  L J Cohen
Journal:  Pharmacotherapy       Date:  1994 May-Jun       Impact factor: 4.705

View more
  8 in total

1.  Risperidone treatment in 12 children with developmental disorders and attention-deficit/hyperactivity disorder.

Authors:  Valsamma Eapen; A K Gururaj
Journal:  Prim Care Companion J Clin Psychiatry       Date:  2005

2.  Short- and long-term efficacy and safety of risperidone in adults with disruptive behavior disorders.

Authors:  Carllo Gagiano; Stephen Read; Lilian Thorpe; Mariëlle Eerdekens; Ilse Van Hove
Journal:  Psychopharmacology (Berl)       Date:  2005-01-25       Impact factor: 4.530

Review 3.  Pharmacotherapy of disorders in mental retardation.

Authors:  M G Aman; A Collier-Crespin; R L Lindsay
Journal:  Eur Child Adolesc Psychiatry       Date:  2000       Impact factor: 4.785

4.  A model of behavioral treatments for self-mutilation behavior in Lesch-Nyhan syndrome.

Authors:  Eric A Zilli; Michael E Hasselmo
Journal:  Neuroreport       Date:  2008-03-05       Impact factor: 1.837

Review 5.  Psychopharmacological treatments in persons with dual diagnosis of psychiatric disorders and developmental disabilities.

Authors:  R Antochi; C Stavrakaki; P C Emery
Journal:  Postgrad Med J       Date:  2003-03       Impact factor: 2.401

6.  Improvement of nonsuicidal self-injury following treatment with antipsychotics possessing strong D1 antagonistic activity: evidence from a report of three cases.

Authors:  Bastian Wollweber; Martin E Keck; Ulrike Schmidt
Journal:  Ther Adv Psychopharmacol       Date:  2015-08

Review 7.  Risperidone for autism spectrum disorder.

Authors:  O S Jesner; M Aref-Adib; E Coren
Journal:  Cochrane Database Syst Rev       Date:  2007-01-24

8.  Pica with learning disability.

Authors:  Pardeep Grewal; Brian Fitzgerald
Journal:  J R Soc Med       Date:  2002-01       Impact factor: 18.000

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.